(NASDAQ: ANIP) Ani Pharmaceuticals's forecast annual revenue growth rate of 11.46% is forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast revenue growth rate of 8.61%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 12.98%.
Ani Pharmaceuticals's revenue in 2026 is $978,379,000.On average, 11 Wall Street analysts forecast ANIP's revenue for 2026 to be $25,818,675,648, with the lowest ANIP revenue forecast at $24,601,246,992, and the highest ANIP revenue forecast at $26,852,341,488. On average, 11 Wall Street analysts forecast ANIP's revenue for 2027 to be $28,552,147,536, with the lowest ANIP revenue forecast at $26,025,408,816, and the highest ANIP revenue forecast at $31,055,915,904.
In 2028, ANIP is forecast to generate $31,078,886,256 in revenue, with the lowest revenue forecast at $27,013,133,952 and the highest revenue forecast at $34,616,320,464.